International Union of Pharmacology XLIV.: Nomenclature for the oxoeicosanoid receptor

被引：50

作者：

Brink, C

Dahlén, SE

Drazen, J

Evans, JF

Hay, DWP

Rovati, GE

Serhan, CN

Shimizu, T

Yokomizo, T

机构：

[1] Hop Broussais, CNRS, UMR 7131, F-75014 Paris, France

[2] Karolinska Inst, Unit Expt Asthma & Allergy, Natl Inst Environm Med, Stockholm, Sweden

[3] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA

[4] Merck & Co Inc, Dept Pharmacol, West Point, PA USA

[5] GlaxoSmithKline, King Of Prussia, PA USA

[6] Div Mol Pharmacol, Milan, Italy

[7] Harvard Univ, Brigham & Womens Hosp,Sch Med, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesia,Res Lab, Boston, MA 02115 USA

[8] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 113, Japan

来源：

PHARMACOLOGICAL REVIEWS | 2004年 / 56卷 / 01期

关键词：

D O I：

10.1124/pr.56.1.4

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Oxoeicosanoids are a family of biologically active arachidonic acid derivatives that have been intimately linked with cellular migration. These metabolites are not only potent chemotaxins but also elicit oxygen radical production as well as induce secretory events in different cells. The most potent native ligand reported is 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE), and the cell membrane receptor activated has now been cloned. This receptor is distinct from those receptors activated by either the prostaglandins or the leukotrienes. The purpose of this review is to briefly summarize the molecular evidence and highlight the significance of this receptor. In addition, an official nomenclature for this oxoeicosanoid receptor is proposed.

引用

页码：149 / 157

页数：9

共 84 条

[1]

Bonizzi G, 1997, J IMMUNOL, V159, P5264

[2] ARACHIDONIC-ACID METABOLISM IN POLYMORPHONUCLEAR LEUKOCYTES .5. UNSTABLE INTERMEDIATE IN FORMATION OF DIHYDROXY ACIDS [J].